BriaCell Approves New Board of Directors and Chairman at Annual and Special Meeting of Shareholders

NEXT STORY
Trillium Therapeutics Reports First Quarter 2019 Financial Results
PREV STORY
CytoDyn Initiates Pre-Clinical Study of Leronlimab (PRO 140) to Prevent NASH with The Cleveland Clinic’s Dr. Daniel J. Lindner, M.D., Ph.D.
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Global Viral Vector Manufacturing Market Outlook to 2026 – Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and Recommendations

author_avatar
NASDAQ Market News

Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC

author_avatar
NASDAQ Market News

Relievant Medsystems Announces Publication of New INTRACEPT Trial Data Demonstrating Long-Term Relief for Chronic Low Back Pain 24 Months Post-Procedure

author_avatar
NASDAQ Market News